查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1827418

止痛药市场（按药物类型、给药途径、适应症和分销管道）—2025-2032 年全球预测

Analgesics Market by Type of Drug, Route of Administration, Indication, Distribution Channel - Global Forecast 2025-2032
出版日期: | 出版商: 360iResearch | 英文 192 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

预计到 2032 年止痛药市场规模将成长至 724.3 亿美元，复合年增长率为 6.99%。

主要市场统计数据
基准年2024年 421.6亿美元
预计2025年 449.6亿美元
预测年份：2032年 724.3亿美元
复合年增长率（%） 6.99%

简要介绍不断发展的镇痛生态系统，重点关注临床需求、监管压力和相关人员策略的创新驱动力

止痛药处于临床需求、监管格局和快速治疗创新的交汇点。患者和临床管理人员需要有效、安全且易于获取的疼痛管理方案，以应对急性和慢性疾病，而製造商则面临阿片类药物管理、製剂创新和供应链韧性方面的紧迫挑战。在此背景下，公共辩论和新兴给药技术正在重塑止痛药的开发、分销和应用方式。

近年来，处方方式已从「一刀切」式转向更加细緻入微、以患者为中心的模式，兼顾疗效、安全性和滥用风险。这一趋势推动了非阿片类和阿片类药物的新产品开发，也引发了人们对能够提高依从性并减少全身暴露的替代给药途径的兴趣。同时，支付方和医疗系统也更严格地审查现实世界的疗效和成本效益，这影响着处方决策和药物的采用时间表。

因此，价值链上的相关人员——製造商、临床医生、经销商和监管机构——必须在短期营运需求与长期策略规划之间取得平衡。本观点为后续章节提供了框架，并提供了一个视角，用于解读将在短期至中期影响产品生命週期和患者疗效的技术、监管和商业性发展。

积极整合临床、技术和监管变化，重新定义发展路径、处方行为和分销策略

在临床、技术和政策力量融合的推动下，镇痛领域正在经历一场变革。临床上，对多药物联合疼痛管理的日益重视、非阿片类药物和联合治疗的兴起以及对高剂量阿片类药物处方依赖的减少，为针对特定疼痛类型的差异化製剂创造了机会。控制释放骨架和经皮平台等製剂科学技术的进步，正在拓展治疗选择，并实现更精准的给药方案。

在监管方面，人们对阿片类药物相关危害日益增长的担忧持续影响着标籤检视、处方指南和上市后监管要求。这促使製造商不仅在分子层面进行创新，还在风险缓解策略方面进行创新，例如开发防滥用配方和整合的病患教育计画。同时，数位健康工具也开始融入镇痛治疗流程，提供远端监控、依从性支援和真实世界数据收集，为临床决策和付款人谈判提供资讯。

商业性来看，随着医疗保健购买者优先考虑基于价值的成果，分销和获取模式也在不断演变。零售、医院和线上药局通路正在适应新的消费者期望和监管要求。这种转变正在创造一个更复杂的竞争格局，在监理合规、供应链管理和证据产生方面的敏捷性将带来策略优势。这些变革性动态正在重新定义疼痛缓解疗法的开发、评估和交付方式。

基于证据的分析，到 2025 年美国关税将如何重塑整个止痛药价值链的供应链、筹资策略和营运弹性。

包括美国将在2025年实施的关税在内的贸易政策决策的累积影响，正在为止痛药供应链和製造业经济带来新的复杂性。影响原材料、活性药物成分和成品的关税可能会增加依赖全球供应商网路的製造商和契约製造製造商的采购成本。为此，企业正在重新评估筹资策略，将某些投入品进行近岸外包，并协商长期供应商协议，以稳定投入成本并最大限度地减少生产中断。

这些调整不仅会影响采购，还会对营运产生影响。製造商可能需要重新评估生产计划、库存缓衝以及与经销商的合约条款，以吸收或转嫁不断上升的成本压力，同时保持价格透明度并遵守报销规定。此外，不断上涨的投入成本可能会影响製剂选择和包装方面的决策，促使企业重新评估各种给药途径和产品剂型的服药成本。

除了直接的成本影响外，关税引发的供应链转变也对市场进入和竞争力具有战略意义。拥有多元化製造地和垂直整合供应链的公司更有能力应对关税相关的波动，而规模较小的公司和采购集中的公司则可能面临更高的营运风险。鑑于这些挑战，相关人员应运用情境规划来识别关键供应节点，对供应商替代方案进行压力测试，并确定投资优先级，以提高供应链的可视性和灵活性。透过预测关税引发的中断并实施切实可行的缓解计划，组织可以保持医疗服务的连续性，并支持患者获得更稳定的疼痛治疗。

详细的细分主导观点将药品类别、给药途径、临床适应症和通路联繫起来，指南产品设计和通路策略

细分洞察揭示了临床需求与机会的交汇点，从而提供对产品、给药方式、适应症和分销动态的详细理解，以明确创新和投资重点。非鸦片类药物包括对乙酰胺酚、非类固醇消炎剂和水杨酸盐，而鸦片类药物进一步细分为可待因、Fentanyl、氢可酮、氢可酮和羟可酮，每种药物都有不同的临床使用和监管考虑。根据给药途径，可提供肌肉注射、静脉注射、口服、直肠给药、局部和经皮选择，口服药物进一步细分为胶囊和片剂，每种药物的配方挑战和患者依从性模式均有所不同。

目录

第一章：前言

第二章调查方法

第三章执行摘要

第四章 市场概况

第五章 市场洞察

  • 增加对非阿片肽类镇痛疗法的投资将推动慢性疼痛治疗​​的创新
  • 对植物来源和植物来源止痛药的需求激增，推动了新产品的推出和配方的变化
  • 数位疗法和穿戴式止痛设备的快速扩张改变了个人化疼痛管理
  • 非处方止痛药中 CBD 成分止痛药的采用将推动利基市场的成长
  • 越来越多地使用人工智慧和机器学习进行预测性疼痛评估和客製化止痛药策略
  • 阿片类药物处方指南的审查力度加大和监管变化将重塑止痛药组合
  • 微创疼痛管理程序的增加推动了医疗设备和药品之间的协同作用
  • 转向以患者为中心的远端医疗疼痛管理平台，增强远端监控和合规性
  • 基于药物基因组学的止痛药配方开发，以提高疗效并减少副作用
  • 针对慢性疼痛讯号路径的基因治疗方法的出现吸引了研发资金

第六章：2025年美国关税的累积影响

第七章：人工智慧的累积影响，2025年

第八章 镇痛药市场（依药物类型）

  • 非阿片类药物
    • 乙酰胺酚
    • 非类固醇消炎剂
    • 水杨酸盐
  • 阿片类药物
    • 可待因
    • Fentanyl
    • 氢可酮
    • 氢可酮
    • 羟可酮

第九章依给药途径分類的止痛药市场

  • 肌肉注射
  • 静脉注射（IV）
  • 口服
    • 胶囊
    • 药片
  • 直肠
  • 外用
  • 经皮

第 10 章 镇痛药市场（按适应症）

  • 急性疼痛
    • 受伤相关疼痛
    • 术后疼痛
  • 慢性疼痛
    • 关节炎
    • 下背部疼痛
    • 癌症痛
    • 神经病变疼痛

第 11 章镇痛药市场（依分销管道）

  • 医院药房
  • 网路药局
  • 零售药局

第十二章 镇痛药市场（按地区）

  • 美洲
    • 北美洲
    • 拉丁美洲
  • 欧洲、中东和非洲
    • 欧洲
    • 中东
    • 非洲
  • 亚太地区

第十三章 止痛药市场（依类别）

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第十四章 各国镇痛药市场

  • 美国
  • 加拿大
  • 墨西哥
  • 巴西
  • 英国
  • 德国
  • 法国
  • 俄罗斯
  • 义大利
  • 西班牙
  • 中国
  • 印度
  • 日本
  • 澳洲
  • 韩国

第十五章 竞争格局

  • 2024年市占率分析
  • 2024年FPNV定位矩阵
  • 竞争分析
    • Johnson & Johnson Services, Inc.
    • Pfizer Inc.
    • Sanofi SA
    • Bayer AG
    • GlaxoSmithKline plc
    • Reckitt Benckiser Group plc
    • Teva Pharmaceutical Industries Ltd.
    • Viatris Inc.
    • Perrigo Company plc
    • Mallinckrodt plc
    • Bristol-Myers Squibb Company
    • Merck KGaA
    • Novartis AG
    • Sun Pharmaceutical Industries Limited
    • Dr. Reddy's Laboratories Ltd.
    • Grunenthal GmbH
    • CSPC Pharmaceutical Group
    • Haleon plc
    • Abbott Laboratories
    • Eli Lilly and Company
    • Lupin Limited
    • CH Boehringer Sohn AG & Co. KG
    • Hikma Pharmaceuticals plc
    • Cipla Limited
Product Code: MRR-434CCDA05184

The Analgesics Market is projected to grow by USD 72.43 billion at a CAGR of 6.99% by 2032.

KEY MARKET STATISTICS
Base Year [2024] USD 42.16 billion
Estimated Year [2025] USD 44.96 billion
Forecast Year [2032] USD 72.43 billion
CAGR (%) 6.99%

A concise introduction to the evolving analgesics ecosystem highlighting clinical demand, regulatory pressures, and innovation drivers shaping stakeholder strategies

The analgesics landscape sits at the intersection of clinical need, regulatory scrutiny, and rapid therapeutic innovation. Patients and clinicians demand effective, safe, and accessible pain management options across acute and chronic conditions, while manufacturers face pressing challenges related to opioid stewardship, formulation innovation, and supply chain resilience. Against this backdrop, public policy debates and emerging delivery technologies are reshaping how analgesics are developed, distributed, and adopted.

Recent years have seen a shift from one-size-fits-all prescribing towards more nuanced, patient-centric approaches that weigh efficacy, safety, and abuse potential. This dynamic is motivating new product development in both non-opioid and opioid categories, as well as renewed interest in alternative routes of administration that can improve adherence and reduce systemic exposure. Simultaneously, payers and health systems are scrutinizing real-world outcomes and cost-effectiveness more closely, which is influencing formulary decisions and adoption timelines.

As a result, stakeholders across the value chain-manufacturers, clinicians, distributors, and regulators-must balance short-term operational imperatives with longer-term strategic planning. This introductory perspective frames the subsequent sections, offering a lens through which to interpret technological, regulatory, and commercial developments that will influence product life cycles and patient outcomes in the near to medium term.

A forward-looking synthesis of clinical, technological, and regulatory shifts that are redefining development pathways, prescribing behavior, and distribution strategies

The analgesics landscape is undergoing transformative shifts driven by converging clinical, technological, and policy forces. Clinically, the emphasis on multimodal pain management has elevated non-opioid therapies and adjunctive strategies, reducing reliance on high-dose opioid prescribing while creating opportunities for differentiated formulations that target specific pain types. Technological advances in formulation science, including controlled-release matrices and transdermal platforms, are expanding therapeutic options and enabling more precise dosing regimens.

On the regulatory front, heightened vigilance around opioid-related harms continues to influence labeling, prescribing guidelines, and post-market surveillance requirements. This has prompted manufacturers to innovate not only at the molecular level but also in risk-mitigation strategies, such as abuse-deterrent formulations and integrated patient education programs. Meanwhile, digital health tools are beginning to integrate with analgesic care pathways, offering remote monitoring, adherence support, and real-world data capture that can inform clinical decision-making and payer negotiations.

Commercially, distribution and access models are evolving as healthcare purchasers prioritize value-based outcomes. Retail, hospital, and online pharmacy channels are each adapting to new consumer expectations and regulatory requirements. These shifts are creating a more complex competitive landscape where agility in regulatory compliance, supply chain management, and evidence generation confers a strategic advantage. Taken together, these transformative dynamics are redefining how analgesic therapies are developed, evaluated, and delivered to patients.

An evidence-based analysis of how United States tariff measures through 2025 could reshape supply chains, sourcing strategies, and operational resilience across the analgesics value chain

The cumulative effects of trade policy decisions, including tariff actions instituted by the United States through 2025, are adding a new layer of complexity to analgesics supply chains and manufacturing economics. Tariff measures affecting raw materials, active pharmaceutical ingredients, and finished goods can increase procurement costs for manufacturers and contract manufacturers that rely on global supplier networks. In response, firms are reevaluating sourcing strategies, nearshoring certain inputs, and negotiating longer-term supplier agreements to stabilize input costs and minimize production disruptions.

These adjustments carry operational implications that extend beyond procurement. Manufacturers may need to revisit production scheduling, inventory buffers, and contractual terms with distributors to absorb or pass through incremental cost pressures while maintaining compliance with pricing transparency and reimbursement rules. Additionally, increased input costs can influence decisions regarding formulation selection and packaging, prompting a reassessment of cost-to-serve across different routes of administration and product formats.

Beyond direct cost impacts, tariff-driven supply chain shifts have strategic ramifications for market access and competitiveness. Companies with diversified manufacturing footprints and vertically integrated supply chains are better positioned to manage tariff-related volatility, while smaller players and those with concentrated sourcing may face heightened operational risk. In light of these challenges, stakeholders should apply scenario planning to identify critical supply nodes, stress-test supplier alternatives, and prioritize investments that enhance supply chain visibility and agility. By anticipating tariff-induced disruptions and implementing pragmatic mitigation measures, organizations can preserve continuity of care and support resilient access to analgesic therapies.

A detailed segmentation-driven perspective connecting drug classes, delivery routes, clinical indications, and distribution pathways to guide product design and channel strategies

Segmentation insights reveal where clinical demand intersects with commercial opportunity, and a granular view of product, delivery, indication, and distribution dynamics helps clarify priorities for innovation and investment. Based on type of drug, the market divides into non-opioids and opioids; non-opioids encompass acetaminophen, non-steroidal anti-inflammatory drugs, and salicylates, while opioids are further segmented into codeine, fentanyl, hydrocodone, morphine, and oxycodone, each with distinct clinical use profiles and regulatory considerations. Based on route of administration, the landscape includes intramuscular, intravenous, oral, rectal, topical, and transdermal delivery options, with oral formats further differentiated into capsules and tablets, and each route implicating different formulation challenges and patient adherence patterns.

Based on indication, pain management needs are categorized into acute and chronic pain; acute pain includes injury-related and postoperative pain where rapid onset and predictable duration are priorities, while chronic pain covers conditions such as arthritis, back pain, cancer pain, and neuropathic pain where long-term safety, tolerability, and functional outcomes matter most. Based on distribution channel, access is governed by hospital pharmacies, online pharmacies, and retail pharmacies, each channel imposing different requirements around inventory management, patient counseling, regulatory compliance, and reimbursement procedures.

Taken together, these segmentation dimensions highlight areas for targeted development. For example, formulations tailored to chronic neuropathic pain may prioritize sustained-release oral or transdermal delivery and require robust tolerability data, while postoperative care solutions emphasize rapid-onset IV or intramuscular products alongside clear protocols for tapering. Channel strategies must align with patient touchpoints: hospital pharmacies are critical for inpatient and perioperative management, retail pharmacies for community access and chronic therapy continuity, and online pharmacies for convenience and adherence support. Integrating these segment-level insights supports product design choices, evidence strategies, and go-to-market planning that reflect real-world clinical use and distribution realities.

A regionalized appraisal of regulatory diversity, payer priorities, and distribution complexities across the Americas, Europe Middle East & Africa, and Asia-Pacific that shape access and adoption

Regional dynamics influence demand patterns, regulatory expectations, and distribution priorities, with distinct implications across the Americas, Europe, Middle East & Africa, and Asia-Pacific. In the Americas, healthcare systems and payer structures emphasize both acute care efficiency and outpatient chronic pain management, with strong attention to opioid stewardship that shapes prescribing behavior and formulary placement. Regulatory and reimbursement environments in the Americas often incentivize evidence generation focused on real-world effectiveness and safety, which affects clinical adoption and procurement decisions.

In Europe, Middle East & Africa, regulatory frameworks vary considerably across jurisdictions, driving the need for localized regulatory strategies and region-specific clinical evidence. Access pathways and distribution models are heterogeneous, ranging from highly centralized national health systems to fragmented private markets, which requires tailored approaches to pricing, reimbursement dossiers, and supply chain logistics. The Asia-Pacific region presents a diverse set of market conditions where rapid urbanization, expanding healthcare infrastructure, and growing demand for patient-centric therapies are accelerating uptake of novel formulations and alternative delivery systems. However, regulatory harmonization is uneven across the region, necessitating strategic sequencing of country launches and adaptive regulatory engagement.

Across all regions, differences in healthcare financing, physician prescribing norms, and patient expectations mean that global product strategies must be adaptable. Manufacturers should align clinical development plans, pharmacovigilance activities, and distribution partnerships with regional priorities to optimize adoption and ensure consistent supply while respecting local regulatory and cultural contexts. This regionalized approach supports more effective resource allocation and mitigates the risk of one-size-fits-all strategies in a geographically diverse global market.

A competitive analysis emphasizing evidence-driven differentiation, strategic partnerships, and supply chain agility as determinants of long-term success in analgesics

Competitive dynamics in analgesics are shaped by a mix of established pharmaceutical companies, specialty manufacturers, and emerging innovators focused on formulation and delivery technologies. Market leaders tend to compete on the basis of clinical evidence, safety profiles, and supply chain reliability, while newer entrants differentiate through novel delivery platforms, abuse-deterrent features, and targeted indication strategies. Partnerships between biopharmaceutical firms and technology providers are becoming more common, enabling the integration of digital health components that support adherence and real-world evidence collection.

Intellectual property strategies remain important where novel molecules or distinctive delivery systems are involved, but competitive positioning increasingly depends on demonstrating real-world benefit and operational excellence across the supply chain. Strategic alliances with contract development and manufacturing organizations, distribution partners, and specialty pharmacies can accelerate market entry and expand reach without necessitating full vertical integration. At the same time, vigilance around pharmacovigilance and regulatory compliance is essential to maintaining trust with prescribers and patients, particularly for opioid therapies.

Going forward, companies that combine robust clinical evidence packages with agile manufacturing footprints and patient-centric service models will be best positioned to capture clinical uptake and sustain long-term relationships with healthcare systems. This requires a coordinated approach that aligns R&D, regulatory, commercial, and supply chain functions to deliver reliable products and measurable outcomes across diverse care settings.

Actionable recommendations for executives to align product innovation, supply chain resilience, evidence generation, and partnerships with evolving clinical and regulatory priorities

Industry leaders should prioritize strategic moves that align product development with clinical practice, regulatory expectations, and resilient supply chain design to maintain competitive advantage. First, investing in abuse-deterrent and patient-centric formulations can address both clinical needs and regulatory scrutiny; focusing development on delivery systems that reduce misuse risk while preserving analgesic efficacy will resonate with prescribers and payers. Second, strengthening supply chain resilience through supplier diversification, nearshoring of critical inputs, and enhanced inventory visibility will mitigate exposure to trade policy shifts and unexpected disruptions.

Third, generating high-quality real-world evidence and health economics data will support reimbursement negotiations and demonstrate value to payers and healthcare systems. Integrating digital tools for adherence monitoring and outcome tracking can augment evidence generation and provide differentiating post-market data. Fourth, tailoring regional launch strategies to local regulatory and payer environments will improve uptake; sequencing launches and adapting promotional messaging to regional clinical norms and distribution channel requirements will optimize resource allocation.

Finally, cultivating strategic partnerships across the ecosystem-from contract manufacturers to specialty pharmacies and digital health vendors-can accelerate commercialization while controlling cost and complexity. By combining these actions, companies can better navigate regulatory pressures, supply chain volatility, and shifting clinical expectations, thereby enhancing the likelihood of sustained adoption and improved patient outcomes.

A transparent and methodical research approach combining expert interviews, literature synthesis, and iterative validation to underpin credible, decision-ready insights

This research employed a multi-method approach combining primary qualitative interviews, secondary literature synthesis, and structured data validation to ensure robust and actionable insights. Primary research involved expert interviews with clinicians, formulary managers, regulatory affairs professionals, and supply chain executives to capture stakeholder perspectives on clinical utility, prescribing trends, regulatory constraints, and operational risks. These conversations prioritized practitioners and decision-makers directly involved in analgesic selection, procurement, and patient management to ground findings in real-world practice.

Secondary research drew on peer-reviewed clinical literature, regulatory guidance documents, and publicly available policy analyses to contextualize trends in analgesic use, safety considerations, and formulation innovations. Where appropriate, regulatory approvals, labeling changes, and guideline updates were reviewed to establish a defensible baseline for analysis. Data triangulation techniques were applied to reconcile differing information sources and to identify consistent patterns that informed segmentation and regional assessments.

Finally, findings were validated through iterative reviews with domain experts and cross-functional stakeholders to confirm interpretability and practical relevance. Limitations were acknowledged explicitly, including the evolving nature of regulatory frameworks and the potential for future policy changes to influence dynamics. This methodological rigor supports the credibility of the conclusions and recommendations presented, while also enabling readers to gauge the applicability of insights to their own strategic contexts.

A concise concluding synthesis that integrates clinical trends, regulatory considerations, supply chain imperatives, and segmentation priorities to guide strategic planning

In summary, the analgesics sector is navigating a period of substantive change driven by clinical shifts toward multimodal pain management, regulatory emphasis on safety and misuse prevention, and commercial pressures that reward evidence of real-world value. These dynamics create both challenges and opportunities for manufacturers and distributors: challenges include managing supply chain exposure to trade policy and regulatory complexity, while opportunities lie in differentiated formulations, alternative delivery systems, and integrated digital support that can improve outcomes and adherence.

Strategically, success will hinge on the ability to align product innovation with payer and prescriber expectations, to build resilient supply chains that absorb policy-induced volatility, and to generate the evidence that convinces healthcare purchasers of clinical and economic value. Regional nuances require tailored approaches to regulatory engagement and market access, and segmentation insights should inform product design choices that match clinical needs with patient preferences and channel realities. By executing on these priorities, organizations can contribute to safer, more effective, and more accessible pain management solutions while protecting commercial performance.

The collective implication is clear: a coordinated, evidence-driven, and regionally sensitive strategy will be essential to navigate near-term disruptions and to position analgesic therapies for long-term relevance in an increasingly outcome-focused healthcare environment.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Rising investment in non-opioid peptide-based pain therapies spurring innovation in chronic pain treatment
  • 5.2. Surge in demand for plant-derived and botanical analgesics fostering new product launches and reformulations
  • 5.3. Rapid expansion of digital therapy and wearable analgesic devices transforming personalized pain management
  • 5.4. Adoption of CBD-infused analgesics in over-the-counter pain management driving niche segment growth
  • 5.5. Increasing use of AI and machine learning for predictive pain assessment and tailored analgesic dosing strategies
  • 5.6. Heightened scrutiny and regulatory shifts in opioid prescribing guidelines reshaping pharmaceutical pain portfolios
  • 5.7. Growth in minimally invasive interventional pain management procedures boosting device and pharmaceutical synergy
  • 5.8. Shift toward patient-centric telemedicine pain management platforms enhancing remote monitoring and compliance
  • 5.9. Development of pharmacogenomic-guided analgesic prescribing improving efficacy and reducing adverse reactions
  • 5.10. Emergence of gene therapy approaches targeting chronic pain signaling pathways attracting R&D funding

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Analgesics Market, by Type of Drug

  • 8.1. Non-Opioids
    • 8.1.1. Acetaminophen
    • 8.1.2. Non-Steroidal Anti-Inflammatory Drugs
    • 8.1.3. Salicylates
  • 8.2. Opioids
    • 8.2.1. Codeine
    • 8.2.2. Fentanyl
    • 8.2.3. Hydrocodone
    • 8.2.4. Morphine
    • 8.2.5. Oxycodone

9. Analgesics Market, by Route of Administration

  • 9.1. Intramuscular
  • 9.2. Intravenous (IV)
  • 9.3. Oral
    • 9.3.1. Capsules
    • 9.3.2. Tablets
  • 9.4. Rectal
  • 9.5. Topical
  • 9.6. Transdermal

10. Analgesics Market, by Indication

  • 10.1. Acute Pain
    • 10.1.1. Injury-related pain
    • 10.1.2. Postoperative pain
  • 10.2. Chronic Pain
    • 10.2.1. Arthritis
    • 10.2.2. Back pain
    • 10.2.3. Cancer pain
    • 10.2.4. Neuropathic pain

11. Analgesics Market, by Distribution Channel

  • 11.1. Hospital Pharmacies
  • 11.2. Online Pharmacies
  • 11.3. Retail Pharmacies

12. Analgesics Market, by Region

  • 12.1. Americas
    • 12.1.1. North America
    • 12.1.2. Latin America
  • 12.2. Europe, Middle East & Africa
    • 12.2.1. Europe
    • 12.2.2. Middle East
    • 12.2.3. Africa
  • 12.3. Asia-Pacific

13. Analgesics Market, by Group

  • 13.1. ASEAN
  • 13.2. GCC
  • 13.3. European Union
  • 13.4. BRICS
  • 13.5. G7
  • 13.6. NATO

14. Analgesics Market, by Country

  • 14.1. United States
  • 14.2. Canada
  • 14.3. Mexico
  • 14.4. Brazil
  • 14.5. United Kingdom
  • 14.6. Germany
  • 14.7. France
  • 14.8. Russia
  • 14.9. Italy
  • 14.10. Spain
  • 14.11. China
  • 14.12. India
  • 14.13. Japan
  • 14.14. Australia
  • 14.15. South Korea

15. Competitive Landscape

  • 15.1. Market Share Analysis, 2024
  • 15.2. FPNV Positioning Matrix, 2024
  • 15.3. Competitive Analysis
    • 15.3.1. Johnson & Johnson Services, Inc.
    • 15.3.2. Pfizer Inc.
    • 15.3.3. Sanofi S.A.
    • 15.3.4. Bayer AG
    • 15.3.5. GlaxoSmithKline plc
    • 15.3.6. Reckitt Benckiser Group plc
    • 15.3.7. Teva Pharmaceutical Industries Ltd.
    • 15.3.8. Viatris Inc.
    • 15.3.9. Perrigo Company plc
    • 15.3.10. Mallinckrodt plc
    • 15.3.11. Bristol-Myers Squibb Company
    • 15.3.12. Merck KGaA
    • 15.3.13. Novartis AG
    • 15.3.14. Sun Pharmaceutical Industries Limited
    • 15.3.15. Dr. Reddy's Laboratories Ltd.
    • 15.3.16. Grunenthal GmbH
    • 15.3.17. CSPC Pharmaceutical Group
    • 15.3.18. Haleon plc
    • 15.3.19. Abbott Laboratories
    • 15.3.20. Eli Lilly and Company
    • 15.3.21. Lupin Limited
    • 15.3.22. C.H. Boehringer Sohn AG & Co. KG
    • 15.3.23. Hikma Pharmaceuticals plc
    • 15.3.24. Cipla Limited

LIST OF FIGURES

  • FIGURE 1. GLOBAL ANALGESICS MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL ANALGESICS MARKET SIZE, BY TYPE OF DRUG, 2024 VS 2032 (%)
  • FIGURE 3. GLOBAL ANALGESICS MARKET SIZE, BY TYPE OF DRUG, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 4. GLOBAL ANALGESICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024 VS 2032 (%)
  • FIGURE 5. GLOBAL ANALGESICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL ANALGESICS MARKET SIZE, BY INDICATION, 2024 VS 2032 (%)
  • FIGURE 7. GLOBAL ANALGESICS MARKET SIZE, BY INDICATION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL ANALGESICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2032 (%)
  • FIGURE 9. GLOBAL ANALGESICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL ANALGESICS MARKET SIZE, BY REGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 11. AMERICAS ANALGESICS MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 12. NORTH AMERICA ANALGESICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 13. LATIN AMERICA ANALGESICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 14. EUROPE, MIDDLE EAST & AFRICA ANALGESICS MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 15. EUROPE ANALGESICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 16. MIDDLE EAST ANALGESICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 17. AFRICA ANALGESICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 18. ASIA-PACIFIC ANALGESICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 19. GLOBAL ANALGESICS MARKET SIZE, BY GROUP, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 20. ASEAN ANALGESICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 21. GCC ANALGESICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 22. EUROPEAN UNION ANALGESICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 23. BRICS ANALGESICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 24. G7 ANALGESICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 25. NATO ANALGESICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 26. GLOBAL ANALGESICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 27. ANALGESICS MARKET SHARE, BY KEY PLAYER, 2024
  • FIGURE 28. ANALGESICS MARKET, FPNV POSITIONING MATRIX, 2024

LIST OF TABLES

  • TABLE 1. ANALGESICS MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
  • TABLE 3. GLOBAL ANALGESICS MARKET SIZE, 2018-2024 (USD MILLION)
  • TABLE 4. GLOBAL ANALGESICS MARKET SIZE, 2025-2032 (USD MILLION)
  • TABLE 5. GLOBAL ANALGESICS MARKET SIZE, BY TYPE OF DRUG, 2018-2024 (USD MILLION)
  • TABLE 6. GLOBAL ANALGESICS MARKET SIZE, BY TYPE OF DRUG, 2025-2032 (USD MILLION)
  • TABLE 7. GLOBAL ANALGESICS MARKET SIZE, BY NON-OPIOIDS, 2018-2024 (USD MILLION)
  • TABLE 8. GLOBAL ANALGESICS MARKET SIZE, BY NON-OPIOIDS, 2025-2032 (USD MILLION)
  • TABLE 9. GLOBAL ANALGESICS MARKET SIZE, BY NON-OPIOIDS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 10. GLOBAL ANALGESICS MARKET SIZE, BY NON-OPIOIDS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 11. GLOBAL ANALGESICS MARKET SIZE, BY NON-OPIOIDS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 12. GLOBAL ANALGESICS MARKET SIZE, BY NON-OPIOIDS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 13. GLOBAL ANALGESICS MARKET SIZE, BY NON-OPIOIDS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 14. GLOBAL ANALGESICS MARKET SIZE, BY NON-OPIOIDS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 15. GLOBAL ANALGESICS MARKET SIZE, BY ACETAMINOPHEN, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 16. GLOBAL ANALGESICS MARKET SIZE, BY ACETAMINOPHEN, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 17. GLOBAL ANALGESICS MARKET SIZE, BY ACETAMINOPHEN, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 18. GLOBAL ANALGESICS MARKET SIZE, BY ACETAMINOPHEN, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 19. GLOBAL ANALGESICS MARKET SIZE, BY ACETAMINOPHEN, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 20. GLOBAL ANALGESICS MARKET SIZE, BY ACETAMINOPHEN, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 21. GLOBAL ANALGESICS MARKET SIZE, BY NON-STEROIDAL ANTI-INFLAMMATORY DRUGS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 22. GLOBAL ANALGESICS MARKET SIZE, BY NON-STEROIDAL ANTI-INFLAMMATORY DRUGS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 23. GLOBAL ANALGESICS MARKET SIZE, BY NON-STEROIDAL ANTI-INFLAMMATORY DRUGS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 24. GLOBAL ANALGESICS MARKET SIZE, BY NON-STEROIDAL ANTI-INFLAMMATORY DRUGS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 25. GLOBAL ANALGESICS MARKET SIZE, BY NON-STEROIDAL ANTI-INFLAMMATORY DRUGS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 26. GLOBAL ANALGESICS MARKET SIZE, BY NON-STEROIDAL ANTI-INFLAMMATORY DRUGS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 27. GLOBAL ANALGESICS MARKET SIZE, BY SALICYLATES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 28. GLOBAL ANALGESICS MARKET SIZE, BY SALICYLATES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 29. GLOBAL ANALGESICS MARKET SIZE, BY SALICYLATES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 30. GLOBAL ANALGESICS MARKET SIZE, BY SALICYLATES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 31. GLOBAL ANALGESICS MARKET SIZE, BY SALICYLATES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 32. GLOBAL ANALGESICS MARKET SIZE, BY SALICYLATES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 33. GLOBAL ANALGESICS MARKET SIZE, BY OPIOIDS, 2018-2024 (USD MILLION)
  • TABLE 34. GLOBAL ANALGESICS MARKET SIZE, BY OPIOIDS, 2025-2032 (USD MILLION)
  • TABLE 35. GLOBAL ANALGESICS MARKET SIZE, BY OPIOIDS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 36. GLOBAL ANALGESICS MARKET SIZE, BY OPIOIDS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 37. GLOBAL ANALGESICS MARKET SIZE, BY OPIOIDS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 38. GLOBAL ANALGESICS MARKET SIZE, BY OPIOIDS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 39. GLOBAL ANALGESICS MARKET SIZE, BY OPIOIDS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 40. GLOBAL ANALGESICS MARKET SIZE, BY OPIOIDS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 41. GLOBAL ANALGESICS MARKET SIZE, BY CODEINE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 42. GLOBAL ANALGESICS MARKET SIZE, BY CODEINE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 43. GLOBAL ANALGESICS MARKET SIZE, BY CODEINE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 44. GLOBAL ANALGESICS MARKET SIZE, BY CODEINE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 45. GLOBAL ANALGESICS MARKET SIZE, BY CODEINE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 46. GLOBAL ANALGESICS MARKET SIZE, BY CODEINE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 47. GLOBAL ANALGESICS MARKET SIZE, BY FENTANYL, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 48. GLOBAL ANALGESICS MARKET SIZE, BY FENTANYL, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 49. GLOBAL ANALGESICS MARKET SIZE, BY FENTANYL, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 50. GLOBAL ANALGESICS MARKET SIZE, BY FENTANYL, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 51. GLOBAL ANALGESICS MARKET SIZE, BY FENTANYL, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 52. GLOBAL ANALGESICS MARKET SIZE, BY FENTANYL, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 53. GLOBAL ANALGESICS MARKET SIZE, BY HYDROCODONE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 54. GLOBAL ANALGESICS MARKET SIZE, BY HYDROCODONE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 55. GLOBAL ANALGESICS MARKET SIZE, BY HYDROCODONE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 56. GLOBAL ANALGESICS MARKET SIZE, BY HYDROCODONE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 57. GLOBAL ANALGESICS MARKET SIZE, BY HYDROCODONE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 58. GLOBAL ANALGESICS MARKET SIZE, BY HYDROCODONE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 59. GLOBAL ANALGESICS MARKET SIZE, BY MORPHINE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 60. GLOBAL ANALGESICS MARKET SIZE, BY MORPHINE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 61. GLOBAL ANALGESICS MARKET SIZE, BY MORPHINE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 62. GLOBAL ANALGESICS MARKET SIZE, BY MORPHINE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 63. GLOBAL ANALGESICS MARKET SIZE, BY MORPHINE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 64. GLOBAL ANALGESICS MARKET SIZE, BY MORPHINE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 65. GLOBAL ANALGESICS MARKET SIZE, BY OXYCODONE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 66. GLOBAL ANALGESICS MARKET SIZE, BY OXYCODONE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 67. GLOBAL ANALGESICS MARKET SIZE, BY OXYCODONE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 68. GLOBAL ANALGESICS MARKET SIZE, BY OXYCODONE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 69. GLOBAL ANALGESICS MARKET SIZE, BY OXYCODONE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 70. GLOBAL ANALGESICS MARKET SIZE, BY OXYCODONE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 71. GLOBAL ANALGESICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 72. GLOBAL ANALGESICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 73. GLOBAL ANALGESICS MARKET SIZE, BY INTRAMUSCULAR, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 74. GLOBAL ANALGESICS MARKET SIZE, BY INTRAMUSCULAR, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 75. GLOBAL ANALGESICS MARKET SIZE, BY INTRAMUSCULAR, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 76. GLOBAL ANALGESICS MARKET SIZE, BY INTRAMUSCULAR, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 77. GLOBAL ANALGESICS MARKET SIZE, BY INTRAMUSCULAR, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 78. GLOBAL ANALGESICS MARKET SIZE, BY INTRAMUSCULAR, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 79. GLOBAL ANALGESICS MARKET SIZE, BY INTRAVENOUS (IV), BY REGION, 2018-2024 (USD MILLION)
  • TABLE 80. GLOBAL ANALGESICS MARKET SIZE, BY INTRAVENOUS (IV), BY REGION, 2025-2032 (USD MILLION)
  • TABLE 81. GLOBAL ANALGESICS MARKET SIZE, BY INTRAVENOUS (IV), BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 82. GLOBAL ANALGESICS MARKET SIZE, BY INTRAVENOUS (IV), BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 83. GLOBAL ANALGESICS MARKET SIZE, BY INTRAVENOUS (IV), BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 84. GLOBAL ANALGESICS MARKET SIZE, BY INTRAVENOUS (IV), BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 85. GLOBAL ANALGESICS MARKET SIZE, BY ORAL, 2018-2024 (USD MILLION)
  • TABLE 86. GLOBAL ANALGESICS MARKET SIZE, BY ORAL, 2025-2032 (USD MILLION)
  • TABLE 87. GLOBAL ANALGESICS MARKET SIZE, BY ORAL, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 88. GLOBAL ANALGESICS MARKET SIZE, BY ORAL, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 89. GLOBAL ANALGESICS MARKET SIZE, BY ORAL, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 90. GLOBAL ANALGESICS MARKET SIZE, BY ORAL, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 91. GLOBAL ANALGESICS MARKET SIZE, BY ORAL, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 92. GLOBAL ANALGESICS MARKET SIZE, BY ORAL, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 93. GLOBAL ANALGESICS MARKET SIZE, BY CAPSULES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 94. GLOBAL ANALGESICS MARKET SIZE, BY CAPSULES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 95. GLOBAL ANALGESICS MARKET SIZE, BY CAPSULES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 96. GLOBAL ANALGESICS MARKET SIZE, BY CAPSULES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 97. GLOBAL ANALGESICS MARKET SIZE, BY CAPSULES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 98. GLOBAL ANALGESICS MARKET SIZE, BY CAPSULES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 99. GLOBAL ANALGESICS MARKET SIZE, BY TABLETS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 100. GLOBAL ANALGESICS MARKET SIZE, BY TABLETS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 101. GLOBAL ANALGESICS MARKET SIZE, BY TABLETS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 102. GLOBAL ANALGESICS MARKET SIZE, BY TABLETS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 103. GLOBAL ANALGESICS MARKET SIZE, BY TABLETS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 104. GLOBAL ANALGESICS MARKET SIZE, BY TABLETS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 105. GLOBAL ANALGESICS MARKET SIZE, BY RECTAL, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 106. GLOBAL ANALGESICS MARKET SIZE, BY RECTAL, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 107. GLOBAL ANALGESICS MARKET SIZE, BY RECTAL, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 108. GLOBAL ANALGESICS MARKET SIZE, BY RECTAL, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 109. GLOBAL ANALGESICS MARKET SIZE, BY RECTAL, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 110. GLOBAL ANALGESICS MARKET SIZE, BY RECTAL, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 111. GLOBAL ANALGESICS MARKET SIZE, BY TOPICAL, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 112. GLOBAL ANALGESICS MARKET SIZE, BY TOPICAL, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 113. GLOBAL ANALGESICS MARKET SIZE, BY TOPICAL, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 114. GLOBAL ANALGESICS MARKET SIZE, BY TOPICAL, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 115. GLOBAL ANALGESICS MARKET SIZE, BY TOPICAL, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 116. GLOBAL ANALGESICS MARKET SIZE, BY TOPICAL, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 117. GLOBAL ANALGESICS MARKET SIZE, BY TRANSDERMAL, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 118. GLOBAL ANALGESICS MARKET SIZE, BY TRANSDERMAL, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 119. GLOBAL ANALGESICS MARKET SIZE, BY TRANSDERMAL, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 120. GLOBAL ANALGESICS MARKET SIZE, BY TRANSDERMAL, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 121. GLOBAL ANALGESICS MARKET SIZE, BY TRANSDERMAL, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 122. GLOBAL ANALGESICS MARKET SIZE, BY TRANSDERMAL, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 123. GLOBAL ANALGESICS MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
  • TABLE 124. GLOBAL ANALGESICS MARKET SIZE, BY INDICATION, 2025-2032 (USD MILLION)
  • TABLE 125. GLOBAL ANALGESICS MARKET SIZE, BY ACUTE PAIN, 2018-2024 (USD MILLION)
  • TABLE 126. GLOBAL ANALGESICS MARKET SIZE, BY ACUTE PAIN, 2025-2032 (USD MILLION)
  • TABLE 127. GLOBAL ANALGESICS MARKET SIZE, BY ACUTE PAIN, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 128. GLOBAL ANALGESICS MARKET SIZE, BY ACUTE PAIN, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 129. GLOBAL ANALGESICS MARKET SIZE, BY ACUTE PAIN, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 130. GLOBAL ANALGESICS MARKET SIZE, BY ACUTE PAIN, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 131. GLOBAL ANALGESICS MARKET SIZE, BY ACUTE PAIN, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 132. GLOBAL ANALGESICS MARKET SIZE, BY ACUTE PAIN, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 133. GLOBAL ANALGESICS MARKET SIZE, BY INJURY-RELATED PAIN, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 134. GLOBAL ANALGESICS MARKET SIZE, BY INJURY-RELATED PAIN, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 135. GLOBAL ANALGESICS MARKET SIZE, BY INJURY-RELATED PAIN, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 136. GLOBAL ANALGESICS MARKET SIZE, BY INJURY-RELATED PAIN, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 137. GLOBAL ANALGESICS MARKET SIZE, BY INJURY-RELATED PAIN, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 138. GLOBAL ANALGESICS MARKET SIZE, BY INJURY-RELATED PAIN, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 139. GLOBAL ANALGESICS MARKET SIZE, BY POSTOPERATIVE PAIN, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 140. GLOBAL ANALGESICS MARKET SIZE, BY POSTOPERATIVE PAIN, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 141. GLOBAL ANALGESICS MARKET SIZE, BY POSTOPERATIVE PAIN, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 142. GLOBAL ANALGESICS MARKET SIZE, BY POSTOPERATIVE PAIN, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 143. GLOBAL ANALGESICS MARKET SIZE, BY POSTOPERATIVE PAIN, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 144. GLOBAL ANALGESICS MARKET SIZE, BY POSTOPERATIVE PAIN, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 145. GLOBAL ANALGESICS MARKET SIZE, BY CHRONIC PAIN, 2018-2024 (USD MILLION)
  • TABLE 146. GLOBAL ANALGESICS MARKET SIZE, BY CHRONIC PAIN, 2025-2032 (USD MILLION)
  • TABLE 147. GLOBAL ANALGESICS MARKET SIZE, BY CHRONIC PAIN, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 148. GLOBAL ANALGESICS MARKET SIZE, BY CHRONIC PAIN, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 149. GLOBAL ANALGESICS MARKET SIZE, BY CHRONIC PAIN, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 150. GLOBAL ANALGESICS MARKET SIZE, BY CHRONIC PAIN, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 151. GLOBAL ANALGESICS MARKET SIZE, BY CHRONIC PAIN, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 152. GLOBAL ANALGESICS MARKET SIZE, BY CHRONIC PAIN, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 153. GLOBAL ANALGESICS MARKET SIZE, BY ARTHRITIS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 154. GLOBAL ANALGESICS MARKET SIZE, BY ARTHRITIS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 155. GLOBAL ANALGESICS MARKET SIZE, BY ARTHRITIS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 156. GLOBAL ANALGESICS MARKET SIZE, BY ARTHRITIS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 157. GLOBAL ANALGESICS MARKET SIZE, BY ARTHRITIS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 158. GLOBAL ANALGESICS MARKET SIZE, BY ARTHRITIS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 159. GLOBAL ANALGESICS MARKET SIZE, BY BACK PAIN, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 160. GLOBAL ANALGESICS MARKET SIZE, BY BACK PAIN, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 161. GLOBAL ANALGESICS MARKET SIZE, BY BACK PAIN, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 162. GLOBAL ANALGESICS MARKET SIZE, BY BACK PAIN, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 163. GLOBAL ANALGESICS MARKET SIZE, BY BACK PAIN, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 164. GLOBAL ANALGESICS MARKET SIZE, BY BACK PAIN, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 165. GLOBAL ANALGESICS MARKET SIZE, BY CANCER PAIN, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 166. GLOBAL ANALGESICS MARKET SIZE, BY CANCER PAIN, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 167. GLOBAL ANALGESICS MARKET SIZE, BY CANCER PAIN, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 168. GLOBAL ANALGESICS MARKET SIZE, BY CANCER PAIN, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 169. GLOBAL ANALGESICS MARKET SIZE, BY CANCER PAIN, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 170. GLOBAL ANALGESICS MARKET SIZE, BY CANCER PAIN, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 171. GLOBAL ANALGESICS MARKET SIZE, BY NEUROPATHIC PAIN, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 172. GLOBAL ANALGESICS MARKET SIZE, BY NEUROPATHIC PAIN, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 173. GLOBAL ANALGESICS MARKET SIZE, BY NEUROPATHIC PAIN, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 174. GLOBAL ANALGESICS MARKET SIZE, BY NEUROPATHIC PAIN, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 175. GLOBAL ANALGESICS MARKET SIZE, BY NEUROPATHIC PAIN, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 176. GLOBAL ANALGESICS MARKET SIZE, BY NEUROPATHIC PAIN, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 177. GLOBAL ANALGESICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 178. GLOBAL ANALGESICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 179. GLOBAL ANALGESICS MARKET SIZE, BY HOSPITAL PHARMACIES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 180. GLOBAL ANALGESICS MARKET SIZE, BY HOSPITAL PHARMACIES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 181. GLOBAL ANALGESICS MARKET SIZE, BY HOSPITAL PHARMACIES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 182. GLOBAL ANALGESICS MARKET SIZE, BY HOSPITAL PHARMACIES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 183. GLOBAL ANALGESICS MARKET SIZE, BY HOSPITAL PHARMACIES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 184. GLOBAL ANALGESICS MARKET SIZE, BY HOSPITAL PHARMACIES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 185. GLOBAL ANALGESICS MARKET SIZE, BY ONLINE PHARMACIES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 186. GLOBAL ANALGESICS MARKET SIZE, BY ONLINE PHARMACIES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 187. GLOBAL ANALGESICS MARKET SIZE, BY ONLINE PHARMACIES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 188. GLOBAL ANALGESICS MARKET SIZE, BY ONLINE PHARMACIES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 189. GLOBAL ANALGESICS MARKET SIZE, BY ONLINE PHARMACIES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 190. GLOBAL ANALGESICS MARKET SIZE, BY ONLINE PHARMACIES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 191. GLOBAL ANALGESICS MARKET SIZE, BY RETAIL PHARMACIES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 192. GLOBAL ANALGESICS MARKET SIZE, BY RETAIL PHARMACIES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 193. GLOBAL ANALGESICS MARKET SIZE, BY RETAIL PHARMACIES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 194. GLOBAL ANALGESICS MARKET SIZE, BY RETAIL PHARMACIES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 195. GLOBAL ANALGESICS MARKET SIZE, BY RETAIL PHARMACIES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 196. GLOBAL ANALGESICS MARKET SIZE, BY RETAIL PHARMACIES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 197. GLOBAL ANALGESICS MARKET SIZE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 198. GLOBAL ANALGESICS MARKET SIZE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 199. AMERICAS ANALGESICS MARKET SIZE, BY SUBREGION, 2018-2024 (USD MILLION)
  • TABLE 200. AMERICAS ANALGESICS MARKET SIZE, BY SUBREGION, 2025-2032 (USD MILLION)
  • TABLE 201. AMERICAS ANALGESICS MARKET SIZE, BY TYPE OF DRUG, 2018-2024 (USD MILLION)
  • TABLE 202. AMERICAS ANALGESICS MARKET SIZE, BY TYPE OF DRUG, 2025-2032 (USD MILLION)
  • TABLE 203. AMERICAS ANALGESICS MARKET SIZE, BY NON-OPIOIDS, 2018-2024 (USD MILLION)
  • TABLE 204. AMERICAS ANALGESICS MARKET SIZE, BY NON-OPIOIDS, 2025-2032 (USD MILLION)
  • TABLE 205. AMERICAS ANALGESICS MARKET SIZE, BY OPIOIDS, 2018-2024 (USD MILLION)
  • TABLE 206. AMERICAS ANALGESICS MARKET SIZE, BY OPIOIDS, 2025-2032 (USD MILLION)
  • TABLE 207. AMERICAS ANALGESICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 208. AMERICAS ANALGESICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 209. AMERICAS ANALGESICS MARKET SIZE, BY ORAL, 2018-2024 (USD MILLION)
  • TABLE 210. AMERICAS ANALGESICS MARKET SIZE, BY ORAL, 2025-2032 (USD MILLION)
  • TABLE 211. AMERICAS ANALGESICS MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
  • TABLE 212. AMERICAS ANALGESICS MARKET SIZE, BY INDICATION, 2025-2032 (USD MILLION)
  • TABLE 213. AMERICAS ANALGESICS MARKET SIZE, BY ACUTE PAIN, 2018-2024 (USD MILLION)
  • TABLE 214. AMERICAS ANALGESICS MARKET SIZE, BY ACUTE PAIN, 2025-2032 (USD MILLION)
  • TABLE 215. AMERICAS ANALGESICS MARKET SIZE, BY CHRONIC PAIN, 2018-2024 (USD MILLION)
  • TABLE 216. AMERICAS ANALGESICS MARKET SIZE, BY CHRONIC PAIN, 2025-2032 (USD MILLION)
  • TABLE 217. AMERICAS ANALGESICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 218. AMERICAS ANALGESICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 219. NORTH AMERICA ANALGESICS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 220. NORTH AMERICA ANALGESICS MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 221. NORTH AMERICA ANALGESICS MARKET SIZE, BY TYPE OF DRUG, 2018-2024 (USD MILLION)
  • TABLE 222. NORTH AMERICA ANALGESICS MARKET SIZE, BY TYPE OF DRUG, 2025-2032 (USD MILLION)
  • TABLE 223. NORTH AMERICA ANALGESICS MARKET SIZE, BY NON-OPIOIDS, 2018-2024 (USD MILLION)
  • TABLE 224. NORTH AMERICA ANALGESICS MARKET SIZE, BY NON-OPIOIDS, 2025-2032 (USD MILLION)
  • TABLE 225. NORTH AMERICA ANALGESICS MARKET SIZE, BY OPIOIDS, 2018-2024 (USD MILLION)
  • TABLE 226. NORTH AMERICA ANALGESICS MARKET SIZE, BY OPIOIDS, 2025-2032 (USD MILLION)
  • TABLE 227. NORTH AMERICA ANALGESICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 228. NORTH AMERICA ANALGESICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 229. NORTH AMERICA ANALGESICS MARKET SIZE, BY ORAL, 2018-2024 (USD MILLION)
  • TABLE 230. NORTH AMERICA ANALGESICS MARKET SIZE, BY ORAL, 2025-2032 (USD MILLION)
  • TABLE 231. NORTH AMERICA ANALGESICS MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
  • TABLE 232. NORTH AMERICA ANALGESICS MARKET SIZE, BY INDICATION, 2025-2032 (USD MILLION)
  • TABLE 233. NORTH AMERICA ANALGESICS MARKET SIZE, BY ACUTE PAIN, 2018-2024 (USD MILLION)
  • TABLE 234. NORTH AMERICA ANALGESICS MARKET SIZE, BY ACUTE PAIN, 2025-2032 (USD MILLION)
  • TABLE 235. NORTH AMERICA ANALGESICS MARKET SIZE, BY CHRONIC PAIN, 2018-2024 (USD MILLION)
  • TABLE 236. NORTH AMERICA ANALGESICS MARKET SIZE, BY CHRONIC PAIN, 2025-2032 (USD MILLION)
  • TABLE 237. NORTH AMERICA ANALGESICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 238. NORTH AMERICA ANALGESICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 239. LATIN AMERICA ANALGESICS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 240. LATIN AMERICA ANALGESICS MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 241. LATIN AMERICA ANALGESICS MARKET SIZE, BY TYPE OF DRUG, 2018-2024 (USD MILLION)
  • TABLE 242. LATIN AMERICA ANALGESICS MARKET SIZE, BY TYPE OF DRUG, 2025-2032 (USD MILLION)
  • TABLE 243. LATIN AMERICA ANALGESICS MARKET SIZE, BY NON-OPIOIDS, 2018-2024 (USD MILLION)
  • TABLE 244. LATIN AMERICA ANALGESICS MARKET SIZE, BY NON-OPIOIDS, 2025-2032 (USD MILLION)
  • TABLE 245. LATIN AMERICA ANALGESICS MARKET SIZE, BY OPIOIDS, 2018-2024 (USD MILLION)
  • TABLE 246. LATIN AMERICA ANALGESICS MARKET SIZE, BY OPIOIDS, 2025-2032 (USD MILLION)
  • TABLE 247. LATIN AMERICA ANALGESICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 248. LATIN AMERICA ANALGESICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 249. LATIN AMERICA ANALGESICS MARKET SIZE, BY ORAL, 2018-2024 (USD MILLION)
  • TABLE 250. LATIN AMERICA ANALGESICS MARKET SIZE, BY ORAL, 2025-2032 (USD MILLION)
  • TABLE 251. LATIN AMERICA ANALGESICS MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
  • TABLE 252. LATIN AMERICA ANALGESICS MARKET SIZE, BY INDICATION, 2025-2032 (USD MILLION)
  • TABLE 253. LATIN AMERICA ANALGESICS MARKET SIZE, BY ACUTE PAIN, 2018-2024 (USD MILLION)
  • TABLE 254. LATIN AMERICA ANALGESICS MARKET SIZE, BY ACUTE PAIN, 2025-2032 (USD MILLION)
  • TABLE 255. LATIN AMERICA ANALGESICS MARKET SIZE, BY CHRONIC PAIN, 2018-2024 (USD MILLION)
  • TABLE 256. LATIN AMERICA ANALGESICS MARKET SIZE, BY CHRONIC PAIN, 2025-2032 (USD MILLION)
  • TABLE 257. LATIN AMERICA ANALGESICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 258. LATIN AMERICA ANALGESICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 259. EUROPE, MIDDLE EAST & AFRICA ANALGESICS MARKET SIZE, BY SUBREGION, 2018-2024 (USD MILLION)
  • TABLE 260. EUROPE, MIDDLE EAST & AFRICA ANALGESICS MARKET SIZE, BY SUBREGION, 2025-2032 (USD MILLION)
  • TABLE 261. EUROPE, MIDDLE EAST & AFRICA ANALGESICS MARKET SIZE, BY TYPE OF DRUG, 2018-2024 (USD MILLION)
  • TABLE 262. EUROPE, MIDDLE EAST & AFRICA ANALGESICS MARKET SIZE, BY TYPE OF DRUG, 2025-2032 (USD MILLION)
  • TABLE 263. EUROPE, MIDDLE EAST & AFRICA ANALGESICS MARKET SIZE, BY NON-OPIOIDS, 2018-2024 (USD MILLION)
  • TABLE 264. EUROPE, MIDDLE EAST & AFRICA ANALGESICS MARKET SIZE, BY NON-OPIOIDS, 2025-2032 (USD MILLION)
  • TABLE 265. EUROPE, MIDDLE EAST & AFRICA ANALGESICS MARKET SIZE, BY OPIOIDS, 2018-2024 (USD MILLION)
  • TABLE 266. EUROPE, MIDDLE EAST & AFRICA ANALGESICS MARKET SIZE, BY OPIOIDS, 2025-2032 (USD MILLION)
  • TABLE 267. EUROPE, MIDDLE EAST & AFRICA ANALGESICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 268. EUROPE, MIDDLE EAST & AFRICA ANALGESICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 269. EUROPE, MIDDLE EAST & AFRICA ANALGESICS MARKET SIZE, BY ORAL, 2018-2024 (USD MILLION)
  • TABLE 270. EUROPE, MIDDLE EAST & AFRICA ANALGESICS MARKET SIZE, BY ORAL, 2025-2032 (USD MILLION)
  • TABLE 271. EUROPE, MIDDLE EAST & AFRICA ANALGESICS MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
  • TABLE 272. EUROPE, MIDDLE EAST & AFRICA ANALGESICS MARKET SIZE, BY INDICATION, 2025-2032 (USD MILLION)
  • TABLE 273. EUROPE, MIDDLE EAST & AFRICA ANALGESICS MARKET SIZE, BY ACUTE PAIN, 2018-2024 (USD MILLION)
  • TABLE 274. EUROPE, MIDDLE EAST & AFRICA ANALGESICS MARKET SIZE, BY ACUTE PAIN, 2025-2032 (USD MILLION)
  • TABLE 275. EUROPE, MIDDLE EAST & AFRICA ANALGESICS MARKET SIZE, BY CHRONIC PAIN, 2018-2024 (USD MILLION)
  • TABLE 276. EUROPE, MIDDLE EAST & AFRICA ANALGESICS MARKET SIZE, BY CHRONIC PAIN, 2025-2032 (USD MILLION)
  • TABLE 277. EUROPE, MIDDLE EAST & AFRICA ANALGESICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 278. EUROPE, MIDDLE EAST & AFRICA ANALGESICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 279. EUROPE ANALGESICS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 280. EUROPE ANALGESICS MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 281. EUROPE ANALGESICS MARKET SIZE, BY TYPE OF DRUG, 2018-2024 (USD MILLION)
  • TABLE 282. EUROPE ANALGESICS MARKET SIZE, BY TYPE OF DRUG, 2025-2032 (USD MILLION)
  • TABLE 283. EUROPE ANALGESICS MARKET SIZE, BY NON-OPIOIDS, 2018-2024 (USD MILLION)
  • TABLE 284. EUROPE ANALGESICS MARKET SIZE, BY NON-OPIOIDS, 2025-2032 (USD MILLION)
  • TABLE 285. EUROPE ANALGESICS MARKET SIZE, BY OPIOIDS, 2018-2024 (USD MILLION)
  • TABLE 286. EUROPE ANALGESICS MARKET SIZE, BY OPIOIDS, 2025-2032 (USD MILLION)
  • TABLE 287. EUROPE ANALGESICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 288. EUROPE ANALGESICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 289. EUROPE ANALGESICS MARKET SIZE, BY ORAL, 2018-2024 (USD MILLION)
  • TABLE 290. EUROPE ANALGESICS MARKET SIZE, BY ORAL, 2025-2032 (USD MILLION)
  • TABLE 291. EUROPE ANALGESICS MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
  • TABLE 292. EUROPE ANALGESICS MARKET SIZE, BY INDICATION, 2025-2032 (USD MILLION)
  • TABLE 293. EUROPE ANALGESICS MARKET SIZE, BY ACUTE PAIN, 2018-2024 (USD MILLION)
  • TABLE 294. EUROPE ANALGESICS MARKET SIZE, BY ACUTE PAIN, 2025-2032 (USD MILLION)
  • TABLE 295. EUROPE ANALGESICS MARKET SIZE, BY CHRONIC PAIN, 2018-2024 (USD MILLION)
  • TABLE 296. EUROPE ANALGESICS MARKET SIZE, BY CHRONIC PAIN, 2025-2032 (USD MILLION)
  • TABLE 297. EUROPE ANALGESICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 298. EUROPE ANALGESICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 299. MIDDLE EAST ANALGESICS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 300. MIDDLE EAST ANALGESICS MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 301. MIDDLE EAST ANALGESICS MARKET SIZE, BY TYPE OF DRUG, 2018-2024 (USD MILLION)
  • TABLE 302. MIDDLE EAST ANALGESICS MARKET SIZE, BY TYPE OF DRUG, 2025-2032 (USD MILLION)
  • TABLE 303. MIDDLE EAST ANALGESICS MARKET SIZE, BY NON-OPIOIDS, 2018-2024 (USD MILLION)
  • TABLE 304. MIDDLE EAST ANALGESICS MARKET SIZE, BY NON-OPIOIDS, 2025-2032 (USD MILLION)
  • TABLE 305. MIDDLE EAST ANALGESICS MARKET SIZE, BY OPIOIDS, 2018-2024 (USD MILLION)
  • TABLE 306. MIDDLE EAST ANALGESICS MARKET SIZE, BY OPIOIDS, 2025-2032 (USD MILLION)
  • TABLE 307. MIDDLE EAST ANALGESICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 308. MIDDLE EAST ANALGESICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 309. MIDDLE EAST ANALGESICS MARKET SIZE, BY ORAL, 2018-2024 (USD MILLION)
  • TABLE 310. MIDDLE EAST ANALGESICS MARKET SIZE, BY ORAL, 2025-2032 (USD MILLION)
  • TABLE 311. MIDDLE EAST ANALGESICS MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
  • TABLE 312. MIDDLE EAST ANALGESICS MARKET SIZE, BY INDICATION, 2025-2032 (USD MILLION)
  • TABLE 313. MIDDLE EAST ANALGESICS MARKET SIZE, BY ACUTE PAIN, 2018-2024 (USD MILLION)
  • TABLE 314. MIDDLE EAST ANALGESICS MARKET SIZE, BY ACUTE PAIN, 2025-2032 (USD MILLION)
  • TABLE 315. MIDDLE EAST ANALGESICS MARKET SIZE, BY CHRONIC PAIN, 2018-2024 (USD MILLION)
  • TABLE 316. MIDDLE EAST ANALGESICS MARKET SIZE, BY CHRONIC PAIN, 2025-2032 (USD MILLION)
  • TABLE 317. MIDDLE EAST ANALGESICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 318. MIDDLE EAST ANALGESICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 319. AFRICA ANALGESICS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 320. AFRICA ANALGESICS MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 321. AFRICA ANALGESICS MARKET SIZE, BY TYPE OF DRUG, 2018-2024 (USD MILLION)
  • TABLE 322. AFRICA ANALGESICS MARKET SIZE, BY TYPE OF DRUG, 2025-2032 (USD MILLION)
  • TABLE 323. AFRICA ANALGESICS MARKET SIZE, BY NON-OPIOIDS, 2018-2024 (USD MILLION)
  • TABLE 324. AFRICA ANALGESICS MARKET SIZE, BY NON-OPIOIDS, 2025-2032 (USD MILLION)
  • TABLE 325. AFRICA ANALGESICS MARKET SIZE, BY OPIOIDS, 2018-2024 (USD MILLION)
  • TABLE 326. AFRICA ANALGESICS MARKET SIZE, BY OPIOIDS, 2025-2032 (USD MILLION)
  • TABLE 327. AFRICA ANALGESICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 328. AFRICA ANALGESICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 329. AFRICA ANALGESICS MARKET SIZE, BY ORAL, 2018-2024 (USD MILLION)
  • TABLE 330. AFRICA ANALGESICS MARKET SIZE, BY ORAL, 2025-2032 (USD MILLION)
  • TABLE 331. AFRICA ANALGESICS MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
  • TABLE 332. AFRICA ANALGESICS MARKET SIZE, BY INDICATION, 2025-2032 (USD MILLION)
  • TABLE 333. AFRICA ANALGESICS MARKET SIZE, BY ACUTE PAIN, 2018-2024 (USD MILLION)
  • TABLE 334. AFRICA ANALGESICS MARKET SIZE, BY ACUTE PAIN, 2025-2032 (USD MILLION)
  • TABLE 335. AFRICA ANALGESICS MARKET SIZE, BY CHRONIC PAIN, 2018-2024 (USD MILLION)
  • TABLE 336. AFRICA ANALGESICS MARKET SIZE, BY CHRONIC PAIN, 2025-2032 (USD MILLION)
  • TABLE 337. AFRICA ANALGESICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 338. AFRICA ANALGESICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 339. ASIA-PACIFIC ANALGESICS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 340. ASIA-PACIFIC ANALGESICS MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 341. ASIA-PACIFIC ANALGESICS MARKET SIZE, BY TYPE OF DRUG, 2018-2024 (USD MILLION)
  • TABLE 342. ASIA-PACIFIC ANALGESICS MARKET SIZE, BY TYPE OF DRUG, 2025-2032 (USD MILLION)
  • TABLE 343. ASIA-PACIFIC ANALGESICS MARKET SIZE, BY NON-OPIOIDS, 2018-2024 (USD MILLION)
  • TABLE 344. ASIA-PACIFIC ANALGESICS MARKET SIZE, BY NON-OPIOIDS, 2025-2032 (USD MILLION)
  • TABLE 345. ASIA-PACIFIC ANALGESICS MARKET SIZE, BY OPIOIDS, 2018-2024 (USD MILLION)
  • TABLE 346. ASIA-PACIFIC ANALGESICS MARKET SIZE, BY OPIOIDS, 2025-2032 (USD MILLION)
  • TABLE 347. ASIA-PACIFIC ANALGESICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 348. ASIA-PACIFIC ANALGESICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 349. ASIA-PACIFIC ANALGESICS MARKET SIZE, BY ORAL, 2018-2024 (USD MILLION)
  • TABLE 350. ASIA-PACIFIC ANALGESICS MARKET SIZE, BY ORAL, 2025-2032 (USD MILLION)
  • TABLE 351. ASIA-PACIFIC ANALGESICS MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
  • TABLE 352. ASIA-PACIFIC ANALGESICS MARKET SIZE, BY INDICATION, 2025-2032 (USD MILLION)
  • TABLE 353. ASIA-PACIFIC ANALGESICS MARKET SIZE, BY ACUTE PAIN, 2018-2024 (USD MILLION)
  • TABLE 354. ASIA-PACIFIC ANALGESICS MARKET SIZE, BY ACUTE PAIN, 2025-2032 (USD MILLION)
  • TABLE 355. ASIA-PACIFIC ANALGESICS MARKET SIZE, BY CHRONIC PAIN, 2018-2024 (USD MILLION)
  • TABLE 356. ASIA-PACIFIC ANALGESICS MARKET SIZE, BY CHRONIC PAIN, 2025-2032 (USD MILLION)
  • TABLE 357. ASIA-PACIFIC ANALGESICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 358. ASIA-PACIFIC ANALGESICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 359. GLOBAL ANALGESICS MARKET SIZE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 360. GLOBAL ANALGESICS MARKET SIZE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 361. ASEAN ANALGESICS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 362. ASEAN ANALGESICS MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 363. ASEAN ANALGESICS MARKET SIZE, BY TYPE OF DRUG, 2018-2024 (USD MILLION)
  • TABLE 364. ASEA